GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » Total Stockholders Equity

Nuvectis Pharma (Nuvectis Pharma) Total Stockholders Equity : $14.02 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma Total Stockholders Equity?

Nuvectis Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $14.02 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Nuvectis Pharma's Book Value per Share for the quarter that ended in Mar. 2024 was $0.76. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Nuvectis Pharma's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.


Nuvectis Pharma Total Stockholders Equity Historical Data

The historical data trend for Nuvectis Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma Total Stockholders Equity Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
-0.01 -11.01 14.22 12.20

Nuvectis Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.27 20.33 16.69 12.20 14.02

Nuvectis Pharma  (NAS:NVCT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Nuvectis Pharma's Book Value per Share for the quarter that ended in Mar. 2024 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Nuvectis Pharma's Debt-to-Equity for the quarter that ended in Mar. 2024 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nuvectis Pharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvectis Pharma (Nuvectis Pharma) Business Description

Traded in Other Exchanges
N/A
Address
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.
Executives
Ron Bentsur director, officer: Chairman & CEO 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri 10 percent owner 27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu officer: Chief Science and Business Off C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh officer: Chief Development Officer C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson officer: Vice President, Finance C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Int. Principal Financial Off. C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan director C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024

Nuvectis Pharma (Nuvectis Pharma) Headlines

From GuruFocus

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

By sperokesalga sperokesalga 05-15-2023

Is Nuvectis Pharma Inc Undervalued Following the Latest Insider Buy?

By GuruFocus Research GuruFocus Editor 05-19-2023